Borrowing Before Profit: A Conditional Answer
The central subject of this series has been venture lending to innovative startups, and the title’s puzzle now has a precise answer. A startup can borrow before it turns a profit when its future value is legible enough through several connected forms of evidence: a credible route to repayment, an investor able to keep supporting the company, collateral with a plausible recovery path, and a contract whose timing fits delayed cash flows. This is a framework for judgment, not a promise that any pre-profit company—or any public venture-debt program—will succeed.
Profit is one form of legibility, not the only one
Profit matters to a lender because it demonstrates that the company can generate more cash than it consumes. But it is a result that often arrives after the spending that creates an innovative product. A biotechnology company may need years of research and trials; a software company may need to build and sell before recurring revenue becomes visible; an industrial technology firm may need to install capacity before customers pay at scale. Waiting for profit before lending would protect a lender, but it could also deny capital during the period when financing changes the company’s prospects.
Venture debt exists because some companies can offer other evidence before that point. The startup can describe what the borrowed cash will accomplish and what event should follow: a completed development program, a commercial launch, a revenue step, a later equity round, or another refinancing opportunity. The venture investor can make the plan more credible by selecting the company, monitoring its progress, and retaining an incentive to support it. A patent or another pledged asset can limit the lender’s loss if the plan fails, particularly when the right can be redeployed to another user. The contract can postpone major repayment until the company has had time to reach the event.
Each mechanism makes a different part of the future visible. A milestone addresses how repayment might occur. Investor support addresses who will help the company reach it. Collateral addresses what may be recovered if it does not occur. Maturity and repayment terms address whether the company can survive long enough for the first two mechanisms to work. None of these is equivalent to current profitability, and none is sufficient by itself.
That distinction explains why venture debt is usually raised after venture equity. Equity investors accept the possibility of total loss in exchange for a share of large upside. Their capital, scrutiny, and continuing involvement can narrow the uncertainty that a lender faces. Venture debt then claims a smaller, more defined part of the company’s future. Later, if recurring cash flow and assets develop, conventional senior debt may be able to rely less on the investor’s promise or a future valuation event.
It also explains why a patent is not a magic substitute for cash flow. A recorded security interest gives the lender a recognized claim and may give them priority over unsecured claimants in bankruptcy. It does not guarantee that the patent will sell. Recovery depends on whether another user can apply the invention, whether buyers can be found, how quickly the transaction can occur, and how much value disappears with the original team. The U.S. evidence found more lending when patent-market liquidity was higher, especially for less firm-specific patents. That pattern supports a salvage-value mechanism, not a universal patent valuation rule.
The venture capitalist’s role is equally conditional. A top-tier investor can serve as a signal of selection quality and a source of monitoring or networks. But the investor’s ability to support a company is tied to the capital available in the relevant fund. When the technology bubble collapsed in 2000, lenders continued lending to IT startups backed by investors with recently raised funds while sharply reducing lending to startups whose investors had older, more constrained funds. The result suggests that financing-chain capacity matters, not merely reputation.
The EIB product extends the same logic through public contract design. It targets firms that have normally raised venture capital and are growing through innovation, yet remain too asset-light or unprofitable for ordinary debt. Its longer maturity, deferred or partly performance-linked payments, possible bullet repayment, warrants, and flexible security or subordination can give R&D-heavy projects more time.